			Home About us Contact

Antituberculosis Drugs (antituberculosi + drug)

Distribution by Scientific Domains

Medical Sciences	50%

Selected Abstracts

Mycobacterium tuberculosis infection of bilateral cervical lymph nodes after renal transplantation

INTERNATIONAL JOURNAL OF UROLOGY, Issue 11 2001
Kiyohito Ishikawa
Abstract We report the case of a 52-year-old man who underwent a renal transplantation and subsequently developed extrapulmonary tuberculosis. The immunosuppressive agent was intravenously administered continuously together with antituberculosis drugs. The tuberculosis improved and renal function has been well preserved for more than 3 years post transplantation. [source]

Association of mycothiol with protection of Mycobacterium tuberculosis from toxic oxidants and antibiotics

MOLECULAR MICROBIOLOGY, Issue 6 2003
Nancy A. Buchmeier
Summary Mycothiol, MSH or 1d - myo -inosityl 2-(N -acetyl- l -cysteinyl)amido-2-deoxy- , - d -glucopyranoside, is an unusual conjugate of N -acetylcysteine (AcCys) with 1d - myo -inosityl 2-acetamido-2-deoxy-,- d -glucopyranoside (GlcN-Ins), and is the major low-molecular-mass thiol in mycobacteria. Mycothiol has antioxidant activity as well as the ability to detoxify a variety of toxic compounds. Because of these activities, MSH is a candidate for protecting Mycobacterium tuberculosis from inactivation by the host during infections as well as for resisting antituberculosis drugs. In order to define the protective role of MSH for M. tuberculosis, we have constructed an M. tuberculosis mutant in Rv1170, one of the candidate MSH biosynthetic genes. During exponential growth, the Rv1170 mutant bacteria produced , 20% of wild-type levels of MSH. Levels of the Rv1170 substrate, GlcNAc-Ins, were elevated, whereas those of the product, GlcN-Ins, were reduced. This establishes that the Rv1170 gene encodes for the major GlcNAc-Ins deacetylase activity (termed MshB) in the MSH biosynthetic pathway of M. tuberculosis. The Rv1170 mutant grew poorly on agar media lacking catalase and oleic acid, and had heightened sensitivities to the toxic oxidant cumene hydroperoxide and to the antibiotic rifampin. In addition, the mutant was more resistant to isoniazid, suggesting a role for MSH in activation of this prodrug. These data indicate that MSH contributes to the protection of M. tuberculosis from oxidants and influences resistance to two first-line antituberculosis drugs. [source]

An unusual case of chylothorax complicating childhood tuberculosis

PEDIATRIC PULMONOLOGY, Issue 6 2008
Erkan Cakir MD
Abstract Endobronchial tuberculosis (EBTB) and chylothorax are rare clinical disorders. The concurrence of these two disorders as manifestations of childhood pulmonary tuberculosis has not been reported. We report a 4-month-old boy presenting with chylothorax as the initial presentation of tuberculosis that has been successfully treated with octreotide, antituberculosis drugs and steroid therapy. Pediatr Pulmonol. 2008; 43:611,614. © 2008 Wiley-Liss, Inc. [source]